Amazon Shares Fall as FTC Plans Ad Pricing Lawsuit 
OpenAI Rejects Apple Trade Secret Theft Claims 
BP Names Ian Tyler Permanent Chairman After Governance Shake-Up 
Trump Secures Drug Pricing Deals With Nine Pharma Companies 
Apple’s Phil Schiller Steps Back as Leadership Shake-Up Accelerates 
South Korea Unveils Record $597 Billion 2027 Budget to Boost AI and Chips 
The Realist’s Case: Lukas Kerrebijn of RD Dubai on the Narrative Dubai’s Agents Won’t Question 
SpaceX Mobile Network Could Cost Up to $130 Billion, Bernstein Says 
OpenAI Nears Astra AI Model Launch With Safety Focus 
MongoDB Stock Sinks 14% as Atlas Growth Misses Expectations 
Shein Shares Slide 9% in Hong Kong IPO Debut 
GM Canada Workers Approve C$1.1 Billion Investment Deal 
Pinterest Stock Falls as CFO Julia Brau Donnelly Resigns 
Honda, Nissan Eye Shared Vehicle Software Platform by 2029 
Street Poller Media and The Boom of the Street Interview Ad Industry 
Amazon Secures 200 MW Wind Power Deals in Sweden 
CIA-Linked Investor Helped Quantum Systems Expand in US 
Add as a preferred source on Google
CHESTERBROOK, Pa., March 20, 2018 -- Trevena, Inc. (NASDAQ:TRVN) today announced that it will be presenting at the Needham & Company 17th Annual Healthcare Conference on Tuesday, March 27, 2018, at 2:30 p.m. EDT in New York, NY.
To join a live audio webcast of the presentation, please visit the Investor section of the Company’s website. Following the conclusion of the presentation, the webcast will be available for replay for 30 days.
About Trevena
Trevena, Inc. is a biopharmaceutical company focused on providing better, safer therapies to patients in pain. The Company has leveraged breakthrough science to discover and develop its investigational product OLINVO™ (oliceridine) Injection for the management of moderate-to-severe acute pain. OLINVO has been granted Breakthrough Therapy designation by the U.S. Food and Drug Administration, and is intended to provide healthcare providers an innovative new option for patients who require an intravenous opioid. The Company also has an early stage pipeline of new chemical entities targeting novel mechanisms of action, including TRV250 for acute migraine, neuropathic pain, and other indications.
Contacts
Trevena, Inc.
Investors:
Jonathan Violin, Ph.D.
Senior Vice President, Scientific Affairs & Investor Relations Officer
610-354-8840 x231
[email protected]
or
Media:
Public Relations
[email protected]
